Comments
Indian Immunologicals Ltd (IIL) will be setting up a new viral antigen manufacturing facility in Phase III of Genome Valley, in Ranga Reddy District, Telangana with an investment of ₹75 crore.
The company also plans to utilise the facility to manufacture Covid-19 vaccines post completion of its R&D with Griffith University, Australia.
With the upcoming facility, IIL expects to increase its capacity to supply additional quantities of high-quality and safe vaccines. The ground-breaking ceremony was held on Wednesday. Spread across 2,000 sq m, the new plant will will be specially designed as a multiproduct facility to cater to the need for viral vaccines in the pipeline that includes Dengue, Zika and Varicella.
The company also inaugurated a new Sterile Filling Facility that was commissioned last year at an additional investment of ₹75 crore.
The unit will boost the production capacity by over 35 per cent and increase the supply capacity to key markets where rabies vaccine is critically needed.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.